Kingsway Financial Services (NYSE:KFS) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsJT Fitzgerald - CEOJames Carbonara - PartnerKent Hansen - CFOMitch Weiman - Senior Portfolio ManagerOperatorGood day, and welcome to the Kingsway fourth quarter 2025 and full year earnings call. At this time, all participants are on a listen-only mode. A question-and-answer session will follow the formal presentation. Please note this conference is being recorded. With me on the call are JT Fitzgerald ...

Karat Packaging (NasdaqGS:KRT) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsAlan Yu - CEOJian Guo - CFOJoshua Axel - Investment AdviserKyle Benvenuto - Equity Research AssociateRoger Pondel - Investor RelationsConference Call ParticipantsRyan Merkel - Research AnalystRyan Meyers - Senior Research AnalystOperatorGood afternoon, and welcome to the Karat Packaging fourth quarter 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, plea ...

Financial Data and Key Metrics Changes - In Q4 2025, EverCommerce generated revenue of $151.2 million, representing a 5.2% year-over-year growth [6][20] - Adjusted EBITDA for the quarter was $44.2 million, with a margin of 29.2%, reflecting operational discipline and efficiency improvements [21][22] - Pro forma revenue for the last twelve months was $591.7 million, indicating a 6.4% year-over-year growth [8][20] Business Line Data and Key Metrics Changes - EverPro and EverHealth verticals accounted for approximately 95% of consolidated revenue, with significant investments in AI capabilities [7][11] - Multi-solution customers grew by 26% year-over-year, with 286,000 customers enabled for more than one solution [16] - The top six payment solutions experienced a 17.4% year-over-year growth in total payment volume [17] Market Data and Key Metrics Changes - The annualized total payments volume expanded to $13 billion, showcasing the growth potential in the payments segment [8] - The company reported a net revenue retention rate of 96%, with multi-solution customers generating NRR above 100% [17] Company Strategy and Development Direction - The company is focused on embedding AI across its platforms to enhance customer experiences and operational efficiency [63] - Investments in AI-driven features and workflows are expected to drive durable growth and improve cash flow generation [26][63] - The acquisition of ZyraTalk is seen as a foundational step towards building an agentic platform for enhanced customer engagement [10][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for 2026, driven by AI investments and improved customer engagement strategies [36][58] - The company anticipates continued operational improvements and a focus on delivering enhanced customer experiences through AI [63] Other Important Information - The company repurchased approximately 2.5 million shares for $24.8 million in Q4 2025, reflecting a commitment to returning value to shareholders [25] - The leadership update included Matt Feierstein taking on the role of CEO for EverPro, emphasizing continuity in strategy execution [18] Q&A Session Summary Question: Customer appetite for AI solutions - Management noted strong uptake in AI functionalities across EverPro, with positive early sales from ZyraTalk integrations [30][31] Question: 2026 growth outlook assumptions - The growth outlook is supported by investments in AI and expectations of re-acceleration in revenue through the year [36][39] Question: Payments revenue decline explanation - The decline in non-top six payment solutions was not significantly related to the MarTech divestiture, with focus on mature and growth segments of the portfolio [42][44] Question: Competitive advantages in the AI landscape - Management highlighted deep niche vertical expertise and a large customer base as key advantages in adapting to AI advancements [45][47] Question: Incremental revenue from no-show prediction tool - The no-show prediction tool is included in packages, with expectations of increased overall ASP as new features are added [51]

Afya (NasdaqGS:AFYA) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsAndre Salles - DirectorFlavio Yoshida - VP of Equity Research for Latin America FinancialsLucca Marquezini - Equity Research AssociateLuis André Blanco - CFOMauricio Cepeda - Equity Research Executive Director of Healthcare and Education LatamRenata Couto - Director of Investor RelationsVirgilio Gibbon - CEOConference Call ParticipantsMarcelo Santos - Senior Sell-side Equity Analyst covering TMT & EducationRenata Couto ...

Financial Data and Key Metrics Changes - The Oncology Institute achieved a revenue increase of approximately 28% year-over-year, surpassing $500 million for the first time in its history, with total revenue for Q4 2025 reaching $142 million, a 41.6% year-over-year growth [5][20] - Adjusted EBITDA for Q4 2025 was $147,000, improving from a loss of $7.8 million in Q4 2024, marking the first profitable quarter from an adjusted EBITDA perspective as a public company [4][24] - SG&A expenses decreased by 2% year-over-year, reflecting operational efficiency, with SG&A as a percentage of revenue dropping from 24.8% to 19.7% [7][23] Business Line Data and Key Metrics Changes - The fee-for-service business grew 9% year-over-year from $136.2 million to $148.5 million, while the capitation business grew 17.2% year-over-year from $68.7 million to $80.5 million [17] - Pharmacy revenue grew 49.6% year-over-year from $179.9 million to $269.2 million, driven by improved prescription attachment rates [18] Market Data and Key Metrics Changes - The company expanded its capitated care model, initiating 9 new capitated contracts in California, Florida, and Nevada, adding approximately 260,000 patient lives under management [5][8] - The Florida Oncology Network platform grew to approximately 207 participating providers, supporting a hybrid model of patient care [10] Company Strategy and Development Direction - The Oncology Institute aims to continue scaling its value-based care platform, with a focus on expanding payer partnerships and achieving sustainable profitability [11][13] - The company plans to launch a proprietary network portal in Q2 2026 to enhance provider engagement and improve operational efficiencies [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year positive adjusted EBITDA in 2026, driven by strong growth in the delegated capitation model [4][11] - The impact of the Inflation Reduction Act on the company's revenue is expected to be minor, with management indicating multiple strategies to offset any potential negative effects [15][16] Other Important Information - The company reduced debt on its convertible preferred note by $24 million, ending the year with $33.6 million in cash [8] - The leadership team was strengthened with new appointments, enhancing the company's ability to scale and execute its growth strategy [10][12] Q&A Session Summary Question: What drove the higher dispensing revenue in the quarter? - Management attributed the strong performance to operational execution in mitigating prescription leakage and strong patient encounter growth related to capitated contracts [30][31] Question: Will the Elevance contract size double in Florida in 2026? - Yes, that is the goal [32] Question: What is the size of the total addressable market for Elevance or Humana? - There is significant opportunity for growth, with many multiples of current capitated revenue available in Florida [34][35] Question: How are margins looking for capitated revenue? - Performance in terms of volume and medical loss ratio (MLR) is as expected, with no surprises [36] Question: Will SG&A improve in 2026? - Improvements are expected, but not to the same degree as in 2025 due to growth investments [65]

Financial Data and Key Metrics Changes - Net sales for Q4 2025 increased by 13.7% to $115.6 million from $101.6 million in Q4 2024, driven by $8.2 million in volume growth and a $6.3 million favorable impact from pricing and product mix [8][9] - Gross profit for Q4 2025 was $39.3 million, compared to $39.8 million in the prior year quarter, with a gross margin of 34.0%, down from 39.2% [10][11] - Net income for Q4 2025 rose by 22.8% to $7.2 million, with a net income margin of 6.2%, up from 5.8% in the prior year quarter [13] Business Line Data and Key Metrics Changes - Sales to chain accounts and distributors, the largest sales channel, increased by 17.5% in Q4 2025, while online sales rose by 1.9% and retail channel sales declined by 4.8% [9] - The new paper bag business category is gaining momentum, contributing to revenue growth and expanding market share [6][7] Market Data and Key Metrics Changes - Eco-friendly product sales grew to 37.3% of total revenue in Q4 2025, up from 34.5% in Q4 2024, indicating a strong demand for sustainable products [7] Company Strategy and Development Direction - The company is focusing on diversifying sourcing and optimizing margins, with a resilient global supply chain maintaining a gross margin of 34% despite higher tariff costs [5][6] - Continued expansion in the paper bag category and the addition of new customer accounts are key strategies for driving top-line growth [17] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing trade volatility but emphasized the company's ability to deliver profitable growth, expecting net sales to increase by approximately 8%-10% in Q1 2026 and low double-digit growth for the full year [16][17] - The company anticipates improvements in gross margin and adjusted EBITDA margin in 2026 under the current global tariff environment [16] Other Important Information - The company repurchased 137,374 shares at an average price of $21.74 per share, with approximately $12.0 million remaining for repurchase under the authorized program [15] - The company ended 2025 with $91.0 million in working capital and maintained financial liquidity of $45.6 million [15] Q&A Session Summary Question: Outlook for 2026 and market assumptions - Management expects low double-digit growth, primarily driven by market share gains in new product categories, despite a competitive environment [20][21] Question: Q1 revenue slowdown and weather impact - Management confirmed that weather conditions, particularly in Texas, caused a slowdown in Q1, but trends are improving as conditions stabilize [22][23] Question: Full year revenue guidance and business opportunities - Management indicated that the revenue guidance includes potential new accounts in the final confirmation stages, but conservatively accounts for testing phases that may delay revenue recognition [27][28] Question: Margin guidance and energy costs - Management confirmed that energy costs are factored into margin outlook, with expectations of a 10%-15% increase in ocean freight shipping costs year-over-year [38] Question: Online sales growth and future platforms - Management anticipates double-digit growth in online sales for 2026, driven by the addition of new platforms and bulk sales strategies [40][41] Question: Demand for eco-friendly products and California market conditions - Demand for eco-friendly products remains strong, particularly for molded fiber and paper bags, while the California market is experiencing a slowdown due to increased competition [48][49]

Surf Air Mobility (NYSE:SRFM) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsDavid Storms - Director of ResearchDeanna White - CEOOliver Reeves - CFOSam Levinson - Head of Investor RelationsSudhin Shahani - Co-founder and DirectorConference Call ParticipantsAmit Dayal - Managing Director and Senior Equity Research AnalystAustin Moeller - Senior Aerospace and Defense Technology AnalystOperatorGood evening. My name is Abby, and I'll be your conference operator today. At this time, I woul ...

Financial Data and Key Metrics Changes - Consolidated revenue for 2025 grew to $135 million, reflecting a 23.4% increase year-over-year, with Q4 revenue up 30.1% to $38.6 million [4][15] - Consolidated adjusted EBITDA for the year was $7.8 million, with Q4 adjusted EBITDA at $2.7 million [4][15] - Consolidated net loss for the year was $10.3 million, with a quarterly net loss of $1.6 million [15] Business Line Data and Key Metrics Changes - KSX segment revenue increased by 63.6% to $20.3 million for Q4 and was up 58.5% to $64.2 million for the year [15] - KSX adjusted EBITDA rose by 28.6% to $2.5 million for Q4 and was up 40.8% to $9.5 million for the year [15] - Extended warranty revenue increased by 6.1% to $18.3 million for Q4 and was up 2.8% to $70.8 million for the year [16] Market Data and Key Metrics Changes - Extended warranty cash sales grew by 11% for Q4 and 9% for the year, with claims costs moderating to a 4.4% increase for the year compared to 6.3% in the prior year [16][17] Company Strategy and Development Direction - The company aims for double-digit organic growth across both KSX and extended warranty segments in 2026, alongside a target of 3-5 acquisitions [5][10] - The strategy focuses on acquiring companies with recurring revenues and strong growth tailwinds, supported by a decentralized management model [3][7] - The company has completed six acquisitions in 2025 and launched a new skilled trades platform, positioning itself for accelerated growth [4][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong organic growth due to the characteristics of the businesses owned and the talent of operator leaders [7][10] - The focus for 2026 includes enhancing value through cross-selling and continued organic growth, with a robust acquisition pipeline [11][13] - Management highlighted the importance of creating a solid foundation for new businesses before pursuing aggressive growth [42] Other Important Information - The company had $8.3 million in cash and cash equivalents at year-end 2025, up from $5.5 million at the end of 2024, while total debt increased to $70.7 million [17][18] - The portfolio LTM adjusted EBITDA was reported at $22 million-$23 million, reflecting the trailing twelve-month performance of the operating businesses [4][19] Q&A Session Summary Question: Update on Digital Diagnostics - Management noted that Digital Diagnostics grew in the high single digits and emphasized the focus on building a solid foundation for future growth [30][42] Question: Acquisition Pipeline - Management confirmed a dual-track acquisition pipeline with strong deal flow and disciplined underwriting criteria [50] Question: Adjustments from Consolidated Adjusted EBITDA to Portfolio LTM EBITDA - The adjustments include pro forma results, differences in modified cash EBITDA for warranty companies, and corporate expenses [52][54] Question: Margin Expansion for Image Solutions and Skilled Trades - Management indicated that investments made in 2025 have set the stage for improved profitability and growth in 2026 [55][56] Question: Double-Digit Growth Drivers - Management expects universal growth across all businesses, driven by revenue growth, efficiency gains, and pricing strategies [57] Question: Tuck-In Acquisitions vs. New Platforms - Management anticipates targeting at least one to two new platform investments, with the remainder being tuck-in acquisitions [58]

Financial Data and Key Metrics Changes - The company ended 2025 with $245.8 million in cash and investments and no debt on its balance sheet [16][41] - Revenue for Q4 2025 was $21.8 million, with a full-year revenue of $55.2 million [43] - R&D expenses for Q4 2025 were $29.7 million, totaling $117.3 million for the full year [43] - G&A expenses for Q4 2025 were $11.2 million, with a full-year total of $68.7 million [43] - The net loss for Q4 2025 was $36.1 million, or $1.78 per share, while the full-year net loss was $164.1 million, or $9.73 per share [43][44] Business Line Data and Key Metrics Changes - The company is focusing on advancing its immunology and inflammation pipeline, particularly the Treg biologic, rezpegaldesleukin [6][7] - Positive results were achieved in phase 2b studies for atopic dermatitis and alopecia areata, validating the Treg mechanism [8][10] - The atopic dermatitis market is projected to grow to approximately $35 billion by the mid-2030s, with significant unmet needs in treatment [11][12] Market Data and Key Metrics Changes - In the U.S., over 15 million people suffer from moderate to severe atopic dermatitis, with only 10%-15% currently receiving biologic treatments [10] - Approximately 50% of patients fail to respond or lose treatment effect over time with current IL-13-based therapies, indicating a significant opportunity for REZPEG [11][12] Company Strategy and Development Direction - The company plans to initiate phase 3 studies for REZPEG in June 2026, with a goal to submit a BLA in 2029 [15][16] - The competitive landscape for late-stage novel mechanisms of action (MOAs) has narrowed, positioning REZPEG favorably [12] - The company aims to leverage its differentiated efficacy and safety profile to capture market share in the atopic dermatitis and alopecia areata markets [12][13] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful outcomes of phase 2 studies and the potential for REZPEG to provide complete disease clearance over time [9][10] - The company expressed confidence in its strong balance sheet, allowing for rapid advancement into phase 3 studies [16][41] - Management noted the importance of achieving a differentiated safety profile compared to existing treatments, particularly JAK inhibitors [13][56] Other Important Information - The company raised approximately $476 million in additional net cash through a public offering and ATM exercises [16][41] - The phase 3 program for REZPEG will evaluate both biologic-naive and treatment-experienced patients [27][61] Q&A Session Summary Question: What type of new data can be expected from the AAD conference presentation? - The upcoming presentation will showcase additional effects of treatment with REZPEG and potential for more patients to achieve SALT 20 responses [49][51] Question: Will ACQ-5 data be included in the phase 3 program? - ACQ-5 will be included in the phase 3 program, and efforts will be made to include it in the label [61] Question: What is the formulation or device for REZPEG being considered? - REZPEG will be launched in an auto-injector device, with weight-banded dosing for ease of administration [71] Question: How many patients completed the extension phase of the alopecia study? - There were 23 patients ongoing in the 16-week extension, and all treatment stops for all patients at either week 36 or week 52 [114] Question: How does REZPEG differentiate from other approaches in type 1 diabetes? - REZPEG offers an outpatient dosing regimen without the need for routine monitoring, contrasting with the IV infusion required for Tzield [108][109]

Financial Data and Key Metrics Changes - Adobe achieved revenue of $6.4 billion in Q1 FY 2026, representing an 11% year-over-year growth [11][32] - GAAP earnings per share (EPS) for the quarter was $4.60, and non-GAAP EPS was $6.06, reflecting 11% and 19% year-over-year growth, respectively [11][32] - Total Adobe ending Annual Recurring Revenue (ARR) reached $26.06 billion, growing 10.9% year-over-year [32] - Cash flows from operations in the quarter were a record $2.96 billion, with ending cash and short-term investments at $6.89 billion [33] Business Line Data and Key Metrics Changes - Subscription revenue for business professionals and consumers was $1.78 billion, increasing 15% year-over-year [32][33] - Creative and marketing professionals' subscription revenue was $4.39 billion, growing 11% year-over-year [17][32] - Monthly Active Users (MAU) for Acrobat and Express grew approximately 20% year-over-year, with Creative Premium MAU crossing 80 million, growing 50% year-over-year [35][14] Market Data and Key Metrics Changes - Adobe's global enterprise offerings saw over 30% year-over-year growth in Adobe Experience Platform (AEP) and applications [10] - The company reported strong momentum in AI-first applications, with ARR from these applications more than tripling year-over-year [11][36] - Firefly subscription and credit pack ending ARR grew 75% quarter-over-quarter, indicating strong adoption in content automation [18][36] Company Strategy and Development Direction - Adobe is focusing on an AI-driven business model, targeting business professionals and consumers through AI-infused product offerings [7][11] - The company aims to empower everyone to create, leveraging its leadership in creativity and productivity tools [6][12] - Adobe is expanding its product portfolio with new offerings like Adobe Acrobat Studio and Adobe Firefly, which are designed to enhance user experience and drive growth [8][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Adobe's ability to capitalize on AI opportunities, emphasizing the importance of customer-centric strategies and innovation [11][39] - The company anticipates continued growth in MAU and usage of AI functionalities, which are expected to drive future revenue [37][38] - Management acknowledged a decline in traditional stock business but remains focused on providing customers with choices between stock and generative AI offerings [37][39] Other Important Information - Adobe's acquisition of Semrush is expected to enhance its offerings in digital marketing and brand visibility [28] - The company serves 99 of the Fortune 100 and is a trusted partner for enterprises in customer experience management [23][24] Q&A Session Summary Question: Insights on RPO and Revenue Visibility - Dan Durn noted that the company is pleased with the momentum in RPO and does not foresee significant changes in revenue visibility [44][45] Question: CEO Transition Expectations - Shantanu Narayen highlighted the importance of product innovation and the board's role in selecting the next CEO, indicating the process may take a few months [49][80] Question: Generative Credit Consumption Trends - David Wadhwani explained that the increase in generative credit consumption is due to higher user engagement and integration of AI into existing workflows [53][54] Question: Revenue Acceleration Factors - Shantanu Narayen discussed the impact of new user adoption and the strength of enterprise solutions on revenue growth, clarifying the stock business's relatively small impact [59][63] Question: Future Growth Initiatives - Shantanu Narayen emphasized the focus on creativity and productivity as key growth drivers, with expectations for continued strong performance in AI-driven offerings [70][75]